Krazati plus Erbitux is well tolerated in KRAS G12C-mutant metastatic colorectal cancer, with manageable side effects and ...
The median overall survival was 6.1 months in the cetuximab group and 4.6 months in the group receiving only supportive care. Rash was seen in 255 of the patients treated with cetuximab.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback